Amfenac Sodium Hydrate is a COX-2 inhibitor.

Product information

CAS Number: 61618-27-7

Molecular Weight: 295.27

Formula: C15H14NNaO4

Chemical Name: sodium 2-(2-amino-3-benzoylphenyl)acetate hydrate

Smiles: O.[Na+].NC1=C(C=CC=C1CC([O-])=O)C(=O)C1C=CC=CC=1

InChiKey: QZNJPJDUBTYMRS-UHFFFAOYSA-M

InChi: InChI=1S/C15H13NO3.Na.H2O/c16-14-11(9-13(17)18)7-4-8-12(14)15(19)10-5-2-1-3-6-10;;/h1-8H,9,16H2,(H,17,18);;1H2/q;+1;/p-1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 150 mg/mL (508.01 mM; Need ultrasonic and warming).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cells transfected to express COX-2 have a higher proliferation rate than those do not. The addition of Amfenac Sodium Hydrate significantly decreases the proliferation rate of all cell lines. Nitric oxide production by macrophages is inhibited by the addition of melanoma conditioned medium, the addition of Amfenac Sodium Hydrate partially overcomes this inhibition. Results show that Amfenac Sodium Hydrate inhibits the release of B-glucuronidase: 5×10-4 M Amfenac Sodium Hydrate inhibits the release of the enzyme 35.3 and 16.3% in the presence of 10-8, and 10-7 M FMLP, respectively. Addition of 10-4 M Amfenac Sodium Hydrate causes 28.3% inhibition of aggregation of polgmorphonuclear leukocgtes (PMNs) during incubation for 16 min with 10-8 M FMLP.

Products are for research use only. Not for human use.